Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bacillus subtilis (strain 168) | Holo-[acyl-carrieir-protein] synthase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | reduced folate carrier family protein | Holo-[acyl-carrieir-protein] synthase | 121 aa | 97 aa | 24.7 % |
Plasmodium vivax | hypothetical protein, conserved | Holo-[acyl-carrieir-protein] synthase | 121 aa | 106 aa | 25.5 % |
Trichomonas vaginalis | conserved hypothetical protein | Holo-[acyl-carrieir-protein] synthase | 121 aa | 117 aa | 24.8 % |
Plasmodium vivax | cloroquine resistance asscociatd protein Cg7, putative | Holo-[acyl-carrieir-protein] synthase | 121 aa | 101 aa | 25.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | nmda type glutamate receptor | 0.0508 | 0.6949 | 0.1439 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0143 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0508 | 0.6949 | 0.6669 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0143 | 0 | 0.5 |
Plasmodium vivax | holo-[acyl-carrier-protein] synthase, putative | 0.0143 | 0 | 0.5 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0481 | 0.6437 | 0.6109 |
Plasmodium falciparum | holo-[acyl-carrier-protein] synthase, putative | 0.0143 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0669 | 1 | 1 |
Chlamydia trachomatis | holo [acyl-carrier protein] synthase | 0.0143 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0143 | 0 | 0.5 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0143 | 0 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0561 | 0.7949 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.5 uM | In vitro inhibitory activity against Holo-[acyl-carrier-protein] synthase was determined using Bacillus subtilis GST-Acp-HTRFassay | ChEMBL. | 14684293 |
IC50 (binding) | = 1.5 uM | In vitro inhibitory activity against Holo-[acyl-carrier-protein] synthase was determined using Bacillus subtilis GST-Acp-HTRFassay | ChEMBL. | 14684293 |
MIC (functional) | = 12.5 uM | Minimum inhibitory concentration required against Streptococcus pneumoniae | ChEMBL. | 14684293 |
MIC (functional) | = 25 uM | Minimum inhibitory concentration required against Escherichia faecalis ATCC strain was determined | ChEMBL. | 14684293 |
MIC (functional) | = 25 uM | Minimum inhibitory concentration required against Escherichia faecalis VRE strain was determined | ChEMBL. | 14684293 |
MIC (functional) | = 50 uM | Minimum inhibitory concentration required against Bacillus subtilis was determined | ChEMBL. | 14684293 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.